Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Market outline PART 05: Pipeline analysis PART 06: Market landscape • Market overview • Five forces analysis PART 07: Market segmentation by drug class • Anticholinergic bronchodilators • Adrenergic bronchodilators • Bronchodilator combinations • Methylxanthines PART 08: Geographical segmentation • Bronchodilators market in Americas • Bronchodilators market in EMEA • Bronchodilators market in APAC PART 09: Decision framework PART 10: Drivers and challenges • Market drivers • Market challenges PART 11: Market trends Innovative technologies for drug delivery Growing usage of home healthcare devices Strong product pipeline PART 12: Vendor landscape • Competitive scenario PART 13: Key vendor analysis • AstraZeneca • Boehringer Ingelheim • F. Hoffmann-La Roche • GlaxoSmithKline • Other prominent vendors PART 14: Appendix • List of abbreviations List of Exhibits Exhibit 01: Types of bronchodilators Exhibit 02: Pipeline landscape Exhibit 03: Pipeline analysis Exhibit 04: Usage of bronchodilators Exhibit 05: Global bronchodilators market 2016-2021 ($ millions) Exhibit 06: Opportunity analysis in global bronchodilators market Exhibit 07: Five forces analysis Exhibit 08: Global anticholinergic bronchodilators market 2016-2021 ($ millions) Exhibit 09: Global adrenergic bronchodilators market 2016-2021 ($ millions) Exhibit 10: Global bronchodilator combinations market 2016-2021 ($ millions) Exhibit 11: Global methylxanthines bronchodilators market 2016-2021 ($ millions) Exhibit 12: Global bronchodilators market based on geography 2016 and 2021 (%) Exhibit 13: Bronchodilators market revenue by geography 2016-2021 ($ millions) Exhibit 14: Market scenario in Americas Exhibit 15: Bronchodilators market in Americas 2016-2021 ($ millions) Exhibit 16: Market scenario in EMEA Exhibit 17: Bronchodilators market in EMEA 2016-2021 ($ millions) Exhibit 18: Market scenario in APAC Exhibit 19: Bronchodilators market in APAC 2016-2021 ($ millions) Exhibit 20: Recent approvals in mAb for bronchodilators market Exhibit 21: Drugs expected to get approval in forecast period Exhibit 22: Recent approvals in bronchodilators market Exhibit 23: Drug approvals in COPD drugs market in past three years Exhibit 24: COPD drug molecules in the stage of registration Exhibit 25: Competitive structure analysis of global bronchodilators market 2016 Exhibit 26: Strategic success factors of companies in global bronchodilators market Exhibit 27: AstraZeneca: Strength assessment Exhibit 28: AstraZeneca: Strategy assessment Exhibit 29: AstraZeneca: Opportunity assessment Exhibit 30: Boehringer Ingelheim: Strength assessment Exhibit 31: Boehringer Ingelheim: Strategy assessment Exhibit 32: Boehringer Ingelheim: Opportunity assessment Exhibit 33: F. Hoffmann-La Roche: Strength assessment Exhibit 34: F. Hoffmann-La Roche: Strategy assessment Exhibit 35: F. Hoffmann-La Roche: Opportunity assessment Exhibit 36: GlaxoSmithKline: Strength assessment Exhibit 37: GlaxoSmithKline: Strategy assessment Exhibit 38: GlaxoSmithKline: Opportunity assessment

AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, GlaxoSmithKline, ALK-Abello, Amgen, Array BioPharma, ASMACURE, Astellas Pharma, Atopix Therapeutics, CHIESI Farmaceutici, Dynavax Technologies, Kissei Pharmaceutical, Kyowa Hakko Kirin, MediciNova, Mitsubishi Tanabe Pharma, Mundipharma International, Nycomed Pharma, Oxagen, Pearl Therapeutics, Pharmaxis, Pulmagen Therapeutics, Regeneron Pharmaceuticals, Revalesio, Sanofi, SolAeroMed, Stallergenes Greer, sterna biologicals, Synairgen, Theron Pharmaceuticals, UCB Pharma, and Verona Pharma.